Greg Finn is a Global Clinical Lead in Hematology-Oncology at Pfizer, a position they have held since 2021. Previously, they served as the Lead in Development Science for Isatuximab Myeloma at Sanofi from 2017 to 2019, overseeing clinical development and regulatory submissions. Earlier, at Merrimack Pharmaceuticals, they held various roles, including Director of Clinical Development & Research and Clinical Scientist Lead for Seribantumab (MM-121), contributing to clinical trial development and implementation. Greg earned a Post-doctoral Fellowship in Cell Biology & Immunology from Harvard Medical School and holds a Ph.D. in Biochemistry & Cancer Biology from the Institute of Technology, Dublin.
This person is not in any teams
This person is not in any offices